BCAR shareholders greenlight Exascale merger, but 95.95% redemption rate leaves only $12M in trust

summarizeSummary

BCAR shareholders approved the Exascale merger, but 95.95% of public shares were redeemed, leaving only $12 million in trust. The deal will close, but the combined company starts with minimal cash.

check_boxKey Events · M&A and Partnerships · BCAR

• Merger Approved, Massive Redemptions

  Shareholders approved the Exascale Labs business combination, but 26,865,211 Class A ordinary shares — 95.95% of the public float — were redeemed, leaving only $12 million in the trust account.

• Minimal Cash at Closing

  The $12 million remaining in trust satisfies the minimum cash closing condition, but provides almost no operating runway for the combined company. Exascale and BCAR do not anticipate additional financing before closing.

• Post-Merger Capital Structure

  The combined company will be renamed Exascale Labs Holdings Inc., trading under 'XLAB' and 'XLABW'. With only $12 million in cash and a $168.7M market cap, the entity is highly leveraged to future capital needs.

• Vote Details Confirm Overwhelming Support

  All proposals passed with over 95% approval from votes cast. The Business Combination Proposal received 24,503,325 votes FOR, 1,120,108 AGAINST, and 35,000 ABSTAIN.

auto_awesomeAnalysis · BCAR · Technology

While BCAR shareholders overwhelmingly approved the merger with Exascale Labs, the vote triggered a massive redemption: 95.95% of public shares were cashed out, leaving just $12 million in the trust. That barely meets the minimum cash closing condition, and the combined company will have almost no SPAC cash cushion. The deal is going through, but the capital structure is threadbare — Exascale will need to generate cash quickly or raise more, and existing BCAR holders who stayed are now in a highly diluted, cash-poor entity. The stock is already near its 52-week low, reflecting the market's dim view of the post-merger outlook.